1,547 reports of this reaction
1.6% of all Abilify Maintena reports
#12 most reported adverse reaction
SCHIZOPHRENIA is the #12 most commonly reported adverse reaction for Abilify Maintena, manufactured by Otsuka America Pharmaceutical, Inc.. There are 1,547 FDA adverse event reports linking Abilify Maintena to SCHIZOPHRENIA. This represents approximately 1.6% of all 96,636 adverse event reports for this drug.
Patients taking Abilify Maintena who experience schizophrenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SCHIZOPHRENIA is a less commonly reported adverse event for Abilify Maintena, but still significant enough to appear in the safety profile.
In addition to schizophrenia, the following adverse reactions have been reported for Abilify Maintena:
The following drugs have also been linked to schizophrenia in FDA adverse event reports:
SCHIZOPHRENIA has been reported as an adverse event in 1,547 FDA reports for Abilify Maintena. This does not prove causation, but indicates an association observed in post-market surveillance data.
SCHIZOPHRENIA accounts for approximately 1.6% of all adverse event reports for Abilify Maintena, making it a notable side effect.
If you experience schizophrenia while taking Abilify Maintena, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.